Targeting HER2 heterogeneity in breast and gastrointestinal cancers.
Trends Cancer
; 10(2): 113-123, 2024 02.
Article
en En
| MEDLINE
| ID: mdl-38008666
ABSTRACT
About 20% of breast and gastric cancers and 3% of colorectal carcinomas overexpress the human epidermal growth factor receptor 2 (HER2) and are sensitive to HER2-directed agents. The expression of HER2 may differ within the same tumoral lesion (spatial intralesional heterogeneity), from different tumor locations (spatial interlesional heterogeneity), and throughout treatments (temporal heterogeneity). Spatial and temporal heterogeneity may impact on response and resistance to HER2-targeting agents and its prevalence and predictive role changes across HER2-overexpressing solid tumors. Therefore, the definition and the characterization of HER2 heterogeneity pose many challenges and its implementation as a reproducible predictive biomarker would help in guiding treatment modulation.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Gástricas
/
Neoplasias Gastrointestinales
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Trends Cancer
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia